Nesheli Hassan Mahmoodi, Tamaddoni Ahmad, Nesheli Mohsen Mahmoodi, Yahyai Alireza, Khabiri Fariba, Hosseinzadeh Fatemeh, Moghaddam Tahereh Galini
Department of Pediatric Haematology, Oncology, Babol University of Medical Sciences, Babol, Iran.
J Pak Med Assoc. 2013 Mar;63(3):324-6.
To evaluate hyperlipidaemia in patients with acute lymphoblastic leukaemia (ALL) receiving L-asparaginase.
A case-control study carried out between October 2007 and October 2010 with 77 patients undergoing chemotherapy at a teaching children's hospital in Babol, Iran. Patients were treated with anti-leukaemic agents according to the protocols for standard-risk and high-risk ALL. Those patients who received asparaginase represented the cases and those who did not receive it were the controls. Biochemical markers were checked during the induction phase chemotherapy. Lipid profile of patients was recorded. Data was analysed using SPSS 16.
Of the 77 patients, 37 (48.05%) received asparaginase therapy and 40 (51.94%) patients did not.The mean peak triglyceride and cholesterol levels during asparaginase therapy in the first group were significantly higher than the levels in the second group.
Severe hyperlipidaemia may be the cause of some morbidity in children receiving asparaginase. Asparaginase-induced hyperlipidaemia should be monitored in ALL patients during the induction phase of treatment.
评估接受L-天冬酰胺酶治疗的急性淋巴细胞白血病（ALL）患者的高脂血症情况。
2007年10月至2010年10月在伊朗巴博尔一家教学儿童医院对77例接受化疗的患者进行了一项病例对照研究。患者根据标准风险和高风险ALL方案接受抗白血病药物治疗。接受天冬酰胺酶治疗的患者为病例组，未接受治疗的患者为对照组。在诱导期化疗期间检查生化指标。记录患者的血脂情况。使用SPSS 16对数据进行分析。
77例患者中，37例（48.05%）接受了天冬酰胺酶治疗，40例（51.94%）未接受。第一组在天冬酰胺酶治疗期间的平均甘油三酯峰值和胆固醇水平显著高于第二组。
严重高脂血症可能是接受天冬酰胺酶治疗儿童出现某些发病情况的原因。在ALL患者治疗的诱导期应监测天冬酰胺酶诱导的高脂血症。
